Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Isracann Biosciences Inc ISCNF

Isracann Biosciences Inc. is a Canada-based cannabis company. The principal business focus of the Company is medical cannabis cultivation and distribution to provide products to the Israeli medical cannabis market, and to develop and validate Natural Health Products (NHP), through the Company’s operating subsidiaries. The Company's segments include Head Office, Medical Cannabis and Natural... see more

GREY:ISCNF - Post Discussion

Isracann Biosciences Inc > IPOT Management
View:
Post by Farlo2020 on Aug 18, 2022 5:41pm

IPOT Management

What are you bozos doing ? 

$0.035 share price. You have a recovering alcoholic junkie from the island as CEO. Costa Cana are home in the wall pot store, mostly on native land , that are barely turning a business. 


what is happening with the farms in Israel ? When is planting and production to begin ? 


the last capital raise is that money to support your guys coke habits because surely it's not helping the company or share price

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities